[cancerpage is a service of Alere]
 


[home]
[search the site]
[my cancerpage]
[ribbon project]
[stories and experiences]
[glossary of terms]
[journal of hope]
[comments]
[about us]
[policies and disclaimers]
[physician and service directories]

Skin Resurfacing May Reduce Risk of Skin Cancer

NEW YORK AUG 25, 2006 (Reuters Health) - Facial resurfacing by three common methods reduces the incidence of actinic keratoses and provides prophylaxis against cutaneous malignancies, results of a small, prospective study suggest.

However, the trichloroacetic acid treatment seemed to be the preferable method to patients.

Dr. Susan M Swetter, from Stanford University Medical Center and colleagues in California compared carbon dioxide laser resurfacing, 30% trichloroacetic acid peel, or 5% fluorouracil cream applied twice daily for 3 weeks.  The 34 patients had histories of facial or scalp actinic keratoses or basal or squamous cell carcinoma.

Eight patients completed treatment with fluorouracil, 10 completed treatment with trichloroacetic acid, and 6 underwent carbon dioxide laser resurfacing.  Five of the patients who dropped out of the study served as the untreated control group.  All the patients were reexamined at 3-month intervals.

Dr. Swetter"s group reports in the August issue of the Archives of Dermatology that all three procedures were successful, resulting in an 83% to 92% reduction in actinic keratoses, and lower incidence of nonmelanoma skin cancer, and a trend toward longer time to development of new skin cancer.  There were no significant differences in efficacy among the three groups.

However, the patients treated with trichloroacetic acid reported "less discomfort, fewer patient complaints, and faster time to healing," the authors report.

SOURCE:

  • Arch Dermatol 2006;142:976-982.



"Reuters content is the intellectual property of Reuters Limited. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon."
 

 MedlinePlus is a resource for health information offered to the public by the US Government. The search box below will direct you to publicly available health information from the National Institutes of Health, the FDA and other government agencies.
Search MEDLINEplus:
 

MEDLINEplus en español

 
We subscribe to the HONcode principles of the Health On the Net Foundation


cancerpage.com 2000
- 2009 . Please send your feedback, comments and suggestions to our staff. Read our policies and terms of service . cancerpage.com is a service of Alere® .
© (2009) Inverness Medical. All Rights Reserved. Alere is a trademark of the Inverness Medical group of companies.